DR-TB Patient Treatment Log Book

Similar documents
Supplementary Appendix

Bedaquiline and delamanid Experience of use in children. Bobojon Sharipov Deputy Director of the Republican Tuberculosis Control Centre

Update on Management of

The Evaluation of Effectiveness and Safety of Novel Shorter. Treatment Regimens for Multidrug-Resistant Tuberculosis

HA Convention 2016 : Special Topic Session 3 May 2016

Diagnosis and Treatment of Tuberculosis, 2011

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor

Treatment of MDR-TB in high HIV- prevalence settings. Hind Satti, M.D. PIH-Lesotho October 20, 2008

Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital

Presented by Leigh Snyman April 2017

SA TB Guidelines The interface with Advanced Clinical Care

Drug Resistant Tuberculosis Self-reporting of Drugrelated. During Treatment

TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM

New TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

Managing Complex TB Cases Diana M. Nilsen, MD, RN

MEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)

REPORT ON GREEN LIGHT COMMITTEE MONITORING MISSION INDONESIA. January Michael Rich, M.D., M.P.H. Date of mission: January 2017

Short MDR-TB Regimen, Uzbekistan

The shorter regimen for MDR-TB: evidence and pitfalls

SURGICAL BREAST PRACTICE NEW PATIENT QUESTIONNAIRE

Multidrug-Resistant Tuberculosis

UCCM ANISHNAABE POLICE SERVICE EMPLOYMENT VISION REPORT

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Overview of the Presentation

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

DOB: / / Please list the names and telephone numbers of the other physicians involved in your care: Name Specialty Phone Address Receive Report (Y/N)

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

The Global Health Impact Index

DATE OF BIRTH: MELANOMA INTAKE

Green Light Committee for the WHO European Region

New and repurposed anti-tb drug introduction and active TB drug-safety monitoring and management

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

3855 Burton Street SE Suite A, Grand Rapids, MI Phone Fax Patient Information. Address: City: State: Zip:

GoPrivateMD General Information & History

MEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY

Short Course Treatment for MDR TB

Patient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio

Controlling TB in the era of HIV

BDQ/DLM COMBINATION: FRENCH-LATVIAN EXPERIENCE AND FUTURE PERSPECTIVES LORENZO GUGLIELMETTI RESIST-TB WEBINAR, 5 APRIL 2018

Anti Tuberculosis Medications: Side Effects & adverse Events

World Health Organization 2010

Joseph S. Weiner, MD, PC Patient History Form

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis

Certainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f

Role of Surgery in the Management of TB. Lee Reichman, MD & Paul Bolanowski, MD

Patient Background. Role of Surgery in the Management of TB. Patient Background CXR 3/20/02

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

COMPREHENSIVE NEW PATIENT QUESTIONNAIRE

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

New Frontiers: Innovation and Access

TOG The Way Forward

Where is your pain located? Please use the diagram below to indicate where most of your pain is located.

Please describe, in detail, when the symptoms began:

NEUROLOGICAL SURGERY, P.C.

PATIENT REGISTRATION

Supplementary Appendix

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Please have your health insurance card(s), a valid picture ID, and any applicable copayment ready when you check-in.

Debbie Onofre, RN, BSN March 18, TB Nurse Case Management March 17 19, 2015 San Antonio, Texas

CECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)

PATIENT HEALTH QUESTIONNAIRE Radiation Oncology

endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3

Caspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166

endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.3

Screening and Treatment Recommendations for Persons Exposed to MDR TB

Silver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother

MINISTRY OF HEALTH, MALAWI. GUIDELINES FOR THE PROGRAMMATIC MANAGEMENT OF MANAGEMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS IN MALAWI

Managing the Patients Response to TB Treatment

New Patient Documentation. Name: (Last) (First) (Middle) Address: (Street) (Apt#) (City) (State) (Zip) Home Phone: ( ) Cell: ( ) Work: ( )

Patient Intake Form for Acupuncture Treatment at Infinite Healing

Tuberculosis in Chicago 2007

Linezolid in the Treatment of Multidrug-Resistant Tuberculosis

NEW PATIENT REGISTRATION FORM

PULMONARY CARE OF CENTRAL FLORIDA, P.A. Date: / /

Columbus Oncology and Hematology Associates 810 Jasonway Ave. Columbus, OH 43214, Ph: , Fax:

Bahl & Bahl Medical Associates PATIENT MEDICAL HISTORY

Allina Health United Lung and Sleep Clinic

MCKAY UROLOGY LINCOLNTON OFFICE PATIENT HISTORY FORM

endtb Clinical and Programmatic Guide for Patient Management with New TB Drugs Version 3.2

Fundamentals of Tuberculosis (TB)

REDROCK MEDICAL GROUP INITIAL HISTORY AND PHYSICAL

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Bedaquiline and delamanid combination as part of a MDR-TB treatment regimen: Current evidence and practices

Chapter 5 Treatment. 5.1 First-Line Antituberculous Treatment

Roll-out of new TB drugs and short-course regimens in the Kyrgyz Republic

NEW PATIENT REGISTRATION PLEASE COMPLETE ALL ITEMS ON EACH PAGE. Name (Last, First, M.I.) Address. City State Zip Code. Phone ( ) Work ( ) Cell ( )

APSR RESPIRATORY UPDATES

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

TB: Siriraj Internal Medicine Board Review 2018

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

TB Nurse Case Management San Antonio, TX. TB Medications and Adverse Effects

CHRISTOPHER BROWN D.O. - TRADITIONAL OSTEOPATHY

Transcription:

REPUBLIC OF KENYA MINISTRY OF HEALTH DR-TB Patient Treatment Log Book Patient Name: Patient Reg. No.: VERSION 2016

DR-TB treatment outcome summary Outcome Mark one Date Cured Died Failed Defaulted Transferred out

DR-TB (Category IV) Treatment Card Registration group County: 1 Sub-County: 2 3 Names: 4 5 6 DR-TB serial number: Date of Registration: Sub-County DR-TB Registration number: 7 Mobile phone number: Male Age: Female Start date No. (If unknown, put year) HIV information Used second line drugs: Yes HIV testing done: Date of Birth: / / If positive, on ARVs: Yes Patient supporter name: No Results: Pos Physical Address: CD4 count: Initial weight (kg): Height (cm): BMI/BMI for Age/Z score: ART Patient No: Pulmonary Extrapulmonary ARV = Antiretrovirals Both Date started: / / Date Started / / CPT = cotrimoxazole preventive therapy If Extrapulmonary, specify site: TB Symptoms Indicate Regimen: Past Medical History Diabetes mellitus Chronic renal insufficiency Chronic hepatitis or cirrhosis Convulsions, epilepsy Cardiovascular disease Psychiatric history Savere malnutrition Other Other medications used Neg Viral Load: If positive on CPT: Yes/No or N/A Cough Current Medication Other lung diseases Current medication Sputum Fever Shortness of breath Night sweats Wheight loss Tick as applicable Outcome No Don t Know If yes tick as applicable in the table below No ART Regimen Telephone Number: Type of TB Yes Date of test: / / Occupation: Previous tuberculosis treatment episodes New (Primary MDR-TB) Relapse Return after default After failure of first line (Cat 1 or 3) After failure of retreatment (Cat 2) Transfer in Other (previously treated without known outcome status) Nearest school/church/mosque: Sex: Select only one Am Amikacin Km Kanamycin Cm Capreomycin Cfx Ciprofloxacin Ofx Ofx Lfx Levofloxacin Mfx Moxifloxacin Gfx Gatifloxacin Pto Prothionamide Eto Ethionamide Cs Cycloserine PAS Para aminosalicilic acid

Anthroprometric Measurements Comments Not Done NC FS MN ND

SCTLC

Month Sputum smear microscopy No. Date* Sample No. Result Sputum smear microscopy Month No. Date* Sample No. Result Culture Month No. Date* Sample No. Result Culture Month No. Date* Sample No. Result Prior** Prior** 0 13 0 13 1 14 1 14 2 15 2 15 3 16 3 16 4 17 4 17 5 18 5 18 6 19 6 19 7 20 7 20 8 21 8 21 9 22 9 22 10 23 10 23 11 24 11 24 GENEXPERT Results (tick where applicable) RESISTANT No AFB seen 1-9 AFB per 100 HPF 0 Scanty (Report no of AFB) 10-99 AFB per 100 HPF + 1-10 AFB per HPF ++ >10 AFB per HPF +++ Notation method for recording cultures No growth reported Fewer than 10 colonies Report no. of colonies 10-1000 colonies + More than 100 colonies ++ Innumerable or confluent growth +++ 12 12

AUDIOMETER FOLLOW UP TOOL Month 0 1 2 3 4 5 6 7 8 9 10 11 12 Date FREQUENCY(dbl) Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left Right Left 500 1,000 2,000 3,000 4,000 6,000 8,000 COMMENTS

RIGHT EAR 8,000 8,000 7,500 7,500 7,000 7,000 6,500 6,500 6,000 6,000 5,500 5,500 Frequency (dbl) Frequency (dbl) LEFT EAR 5,000 4,500 4,000 3,500 5,000 4,500 4,000 3,500 3,000 3,000 2,500 2,500 2,000 2,000 1,500 1,500 1,000 1,000 500 500 0 1 2 3 4 5 6 7 8 Month of Treatment 9 10 11 12 0 1 2 3 4 5 6 7 8 Month of Treatment 9 10 11 12

DR-TB DRUG SIDE EFFECT MONITORING FORM Intensive phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome

DR-TB DRUG SIDE EFFECT MONITORING FORM Intensive phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome

DR-TB DRUG SIDE EFFECT MONITORING FORM Continuation phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome

DR-TB DRUG SIDE EFFECT MONITORING FORM Continuation phase - Adverse effect (indicate grading*) Month/Date Month of treatment Management Date side effect was detected Abdominal pain Constipation Decreased hearing Depression Diarrhea Dizziness Fatigue Fever Headache Joint pain Nausea Psychosis Rash Skin colorization Tinnitus Tremors Vision changes Vomiting Others (list) * Grading: 1 = mild; requiring no intervention 2 = moderate; requiring palliative intervention ** Indicate in the first column the month of treatment that intensive phase ended 3 = severe; requiring change in treatment Outcome

DR-TB REGIMEN (Date treatment started and dosage (mg), change of dosage, and ceasation of drugs) Drug INH R Z E High Dose-INH KM AM CM LFX MFX ETO PTO CS Pas BDQ DEL CFZ LZD AMX/CLAV IMP Date treatment started Initial Dosage Date of Dosage revision Adjusted Dose Reason for adjusting dosage Date drug was stopped Reason for stopping the drug

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Reason for missed drug Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 INH R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed N Not Supervised X Drug not taken Comments: 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Daily observation of drug intake (One table per month) Month Date 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 INH Reason for missed drug R E Z High Dose-INH AM KM CM LFX MFX PTO ETO CS PAS AMX/CLAV LZD CFX BDQ DLM IMP Mark in the boxes O Daily Observed Comments: N X Not Supervised Drug not taken